Patents Assigned to TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.
-
Publication number: 20210001061Abstract: A system may limit the number of times an inhalation device transmits inhalation data to a single time to reduce the battery usage of the inhalation device. The system may include an inhalation device that has medicament and an electronics module. The system may limit the number of times the inhalation device transmits new inhalation data to any mobile device to a single time by causing the server to receive the new inhalation data from one of the mobile devices and causing the server to transmit the new inhalation data to other of the mobile devices prior to the other mobile devices transmitting a request for the new inhalation data to the inhalation device. The inhalation device may include a Quick Response (QR) code, and a mobile application may determine at least one of a medication type or a number of doses of the inhalation device from the QR code.Type: ApplicationFiled: July 6, 2020Publication date: January 7, 2021Applicants: Norton (Waterford) Limited, Teva Branded Pharmaceutical Products R&D, Inc.Inventors: Enrique Calderon Oliveras, Amir Kesten
-
Patent number: 10653704Abstract: This invention provides a process for preparing an inhalable active pharmaceutical ingredient comprising the steps of heating a suspension of an active pharmaceutical ingredient in a liquefied propellant in a vessel, evaporating the propellant and collecting the resultant powder.Type: GrantFiled: October 16, 2015Date of Patent: May 19, 2020Assignee: Teva Branded Pharmaceutical Products R&D, Inc.Inventors: Mukul Dalvi, Jacquelyn McCabe
-
Patent number: 10188811Abstract: A nasal spray device for the delivery of a pharmaceutical formulation to the nasal cavity in metered doses. The device includes: a pressurised aerosol canister including a vial containing a pharmaceutical formulation including an active ingredient, a propellant and, optionally, a co-solvent, the aerosol canister further including a metering valve having a valve stem; and an actuator for the aerosol canister, the actuator including a stem block having a receptacle into which the valve stem of metering valve of the aerosol canister is received and axially located and being displaceable relative to the vial of the aerosol canister to actuate the metering valve of the aerosol canister, a sump extending below the receptacle, the stem block further defining a discharge orifice for the pharmaceutical formulation and a transfer channel through which a dispensed dose of the pharmaceutical formulation is able to pass from the sump to the discharge orifice.Type: GrantFiled: September 25, 2015Date of Patent: January 29, 2019Assignees: TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC., IVAX PHARMACEUTICALS IRELANDInventors: Xian-Ming Zeng, Declan Walsh, Jade Ching-Ying Ly, Armando Morales
-
Patent number: 10034866Abstract: This invention relates to a solution formulation comprising a tiotropium salt, 12-20% ethanol, 0.1-1.5% of water, 0.05-0.10% citric acid (or other organic acid) and an HFA propellant, wherein the percentages are percentages by weight based on the total weight of the formulation. The invention also provides a p MDI comprising a canister containing the formulation.Type: GrantFiled: October 5, 2016Date of Patent: July 31, 2018Assignee: TEVA Branded Pharmaceutical Products R&D, Inc.Inventor: Xian-Ming Zeng
-
Patent number: 9980904Abstract: This invention provides a process for preparing an inhalable dry powder pharmaceutical formulation comprising the step of heating a sealed wrapper containing a desiccant and an inhaler or a capsule, the inhaler or capsule further containing a dry powder formulation comprising an inhalable active pharmaceutical ingredient and a carrier, wherein the wrapper forms a barrier to the ingress of moisture and wherein heating the sealed wrapper and its contents is performed at a temperature of 30-50° C.Type: GrantFiled: October 16, 2015Date of Patent: May 29, 2018Assignee: Teva Branded Pharmaceutical Products R&D, Inc.Inventors: Mukul Dalvi, Seah Kee Tee
-
Publication number: 20180015035Abstract: This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 pg; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose.Type: ApplicationFiled: January 20, 2016Publication date: January 18, 2018Applicant: Teva Branded Pharmaceutical Products R&D, Inc.Inventors: Mukul Dalvi, Seah Kee Tee
-
Publication number: 20170239269Abstract: This invention provides a process for preparing an inhalable active pharmaceutical ingredient comprising the steps of heating a suspension of an active pharmaceutical ingredient in a liquefied propellant in a vessel, evaporating the propellant and collecting the resultant powder.Type: ApplicationFiled: October 16, 2015Publication date: August 24, 2017Applicant: Teva Branded Pharmaceutical Products R&D, Inc.Inventors: Mukul Dalvi, Jacquelyn McCabe
-
Publication number: 20170239177Abstract: This invention provides a process for preparing an inhalable dry powder pharmaceutical formulation comprising the step of heating a sealed wrapper containing a desiccant and an inhaler or a capsule, the inhaler or capsule further containing a dry powder formulation comprising an inhalable active pharmaceutical ingredient and a carrier, wherein the wrapper forms a barrier to the ingress of moisture and wherein heating the sealed wrapper and its contents is performed at a temperature of 30-50° C.Type: ApplicationFiled: October 16, 2015Publication date: August 24, 2017Applicant: Teva Branded Pharmaceutical Products R&D, Inc.Inventors: Mukul Dalvi, Seah Kee Tee
-
Patent number: 9707295Abstract: The present invention provides a solution formulation for inhalation comprising: a liquid phase; an active ingredient containing a carboxylic ester in which the oxygen atom is covalently bound to a quaternary nitrogen-containing heterocycle, dissolved in the liquid phase; and a magnesium or calcium salt, dissolved in the liquid phase. The formulation is particularly suited to pMDIs and nebulizers.Type: GrantFiled: May 3, 2016Date of Patent: July 18, 2017Assignee: Teva Branded Pharmaceutical Products R&D, Inc.Inventors: Mukul Dalvi, Libo Wu
-
Patent number: 9655969Abstract: This invention relates to a solution formulation containing a tiotropium salt, 12-20% ethanol, 0.1-1.5% of water, 0.05-0.10% citric acid (or other organic acid) and an HFA propellant, wherein the percentages are percentages by weight based on the total weight of the formulation. The invention also provides a pMDI comprising a canister containing the formulation.Type: GrantFiled: December 6, 2012Date of Patent: May 23, 2017Assignee: Teva Branded Pharmaceutical Products R&D, Inc.Inventor: Xian-Ming Zeng
-
Publication number: 20170027960Abstract: The present invention provides an inhalable pharmaceutical solution aerosol comprising beclometasone dipropionate, ethanol and a propellant selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, wherein the aerosol has a droplet size having a mass median aerodynamic diameter of 0.5-2.0 ?m, for use in the treatment of asthma in an individual with impaired hand-inhalation coordination.Type: ApplicationFiled: October 14, 2016Publication date: February 2, 2017Applicant: Teva Branded Pharmaceutical Products R&D, Inc.Inventor: Gokul H. Gopalan
-
Publication number: 20160250197Abstract: Accordingly, the present invention provides a solution formulation for inhalation comprising: a liquid phase; an active ingredient having a functional group which is susceptible to hydrolysis and/or solvolysis, dissolved in the liquid phase; and a magnesium or calcium salt, dissolved in the liquid phase. The formulation is particularly suited to pMDIs and nebulisers.Type: ApplicationFiled: November 21, 2014Publication date: September 1, 2016Applicant: Teva Branded Pharmaceutical Products R&D, Inc.Inventors: Mukul Dalvi, Libo Wu
-
Publication number: 20160243320Abstract: This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose.Type: ApplicationFiled: October 6, 2014Publication date: August 25, 2016Applicant: TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.Inventors: Mukul Dalvi, Seah Kee Tee
-
Publication number: 20160243241Abstract: The present invention provides a solution formulation for inhalation comprising: a liquid phase; an active ingredient containing a carboxylic ester in which the oxygen atom is covalently bound to a quaternary nitrogen-containing heterocycle, dissolved in the liquid phase; and a magnesium or calcium salt, dissolved in the liquid phase. The formulation is particularly suited to pMDIs and nebulisers.Type: ApplicationFiled: May 3, 2016Publication date: August 25, 2016Applicant: Teva Branded Pharmaceutical Products R&D, Inc.Inventors: Mukul DALVI, Libo WU
-
Patent number: 9415008Abstract: This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose.Type: GrantFiled: January 20, 2016Date of Patent: August 16, 2016Assignee: Teva Branded Pharmaceutical Products R&D, Inc.Inventors: Mukul Dalvi, Seah Kee Tee
-
Publication number: 20160206559Abstract: This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of fluticasone propionate per actuation is less than 100 ?g; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose.Type: ApplicationFiled: January 20, 2016Publication date: July 21, 2016Applicant: Teva Branded Pharmaceutical Products R&D, Inc.Inventors: Mukul DALVI, Seah Kee TEE
-
Patent number: D892855Type: GrantFiled: February 22, 2019Date of Patent: August 11, 2020Assignee: Teva Branded Pharmaceutical Products R&D, Inc.Inventor: Xinyu Liu
-
Patent number: D912072Type: GrantFiled: February 22, 2019Date of Patent: March 2, 2021Assignee: Teva Branded Pharmaceutical Products R&D, Inc.Inventors: Xinyu Liu, Amir Zur
-
Patent number: D913301Type: GrantFiled: February 22, 2019Date of Patent: March 16, 2021Assignee: Teva Branded Pharmaceutical Products R&D, Inc.Inventor: Xinyu Liu
-
Patent number: D920996Type: GrantFiled: February 22, 2019Date of Patent: June 1, 2021Assignee: Teva Branded Pharmaceutical Products R&D, Inc.Inventors: Xinyu Liu, Amir Zur